These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 10094544)

  • 21. Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study.
    Nadar S; Lim HS; Beevers DG; Lip GY
    J Hum Hypertens; 2002 Dec; 16(12):815-7. PubMed ID: 12522461
    [No Abstract]   [Full Text] [Related]  

  • 22. [SBU should investigate what is an evidence-based and cost-effective use of statins].
    Hjemdahl P; Allhammar A; Heaton C; Hulting J; Kahan T; Malmström R; Martinsson A; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
    Lakartidningen; 2009 Aug 5-18; 106(32-33):1992-4. PubMed ID: 19764381
    [No Abstract]   [Full Text] [Related]  

  • 23. A randomised comparison of simvastatin versus simvastatin and low cholesterol diet in the treatment of hypercholesterolaemia.
    Thuraisingham S; Tan KH; Chong KS; Yap SF; Pasamanikam K
    Int J Clin Pract; 2000 Mar; 54(2):78-84. PubMed ID: 10824361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Type 2 diabetics are high risk patients. Concerning LDL-cholesterol to approach effectively to two sources].
    MMW Fortschr Med; 2005 Nov; 147(44):52-3. PubMed ID: 16302495
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment with statins: further data from the Heart Protection Study].
    Tonstad S; Holme I
    Tidsskr Nor Laegeforen; 2002 Nov; 122(29):2777-80. PubMed ID: 12523144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rx for uncertainty. Does a popular cholesterol-lowering drug do what it's supposed to do?
    Law BM
    Diabetes Forecast; 2008 Mar; 61(3):19. PubMed ID: 18446972
    [No Abstract]   [Full Text] [Related]  

  • 27. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood.
    Stefanutti C; Lucani G; Vivenzio A; Di Giacomo S
    Drugs Exp Clin Res; 1999; 25(1):23-8. PubMed ID: 10337501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of ezetimibe in the management of patients with atherosclerosis.
    Hamilton P
    Coron Artery Dis; 2009 Mar; 20(2):169-74. PubMed ID: 19106797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment.
    Miettinen TA; Gylling H;
    Clin Chim Acta; 2007 Apr; 379(1-2):53-8. PubMed ID: 17258182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simvastatin effects in normo- and hypercholesterolaemic patients with peripheral arterial occlusive disease: a pilot study.
    Grodzińska L; Starzyk D; Bieroń K; Goszcz A; Korbut R
    Basic Clin Pharmacol Toxicol; 2005 Jun; 96(6):413-9. PubMed ID: 15910404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug.
    Cheetham TC; Chan J; Benson V; Richmond C; Levin E; Campen D
    Am J Manag Care; 2005 Sep; 11(9):546-52. PubMed ID: 16159044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterolemic coronary subjects.
    Gylling H; Miettinen TA
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):19-23. PubMed ID: 12125225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ezetimibe--an update.
    Drug Ther Bull; 2009 Aug; 47(8):91-5. PubMed ID: 19654419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Palmer G;
    Am J Cardiol; 2004 Sep; 94(6):720-4. PubMed ID: 15374773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
    Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Practical aspects of "Heart Protection Studies"].
    Susekov AV
    Ter Arkh; 2004; 76(2):91-5. PubMed ID: 15106426
    [No Abstract]   [Full Text] [Related]  

  • 39. Antioxidant effect of simvastatin is not enhanced by its association with alpha-tocopherol in hypercholesterolemic patients.
    Pereira EC; Bertolami MC; Faludi AA; Sevanian A; Abdalla DS
    Free Radic Biol Med; 2004 Nov; 37(9):1440-8. PubMed ID: 15454283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemia.
    Kastelein JJ; Sankatsing RR
    Int J Clin Pract; 2005 Dec; 59(12):1464-71. PubMed ID: 16351680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.